General MedicationsINJECTIONStandard
CABLIVI
CAPLACIZUMAB-YHDP
Standard Dose
11MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview CABLIVI is listed in Drugs@FDA under application 761112 (BLA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient CAPLACIZUMAB-YHDP Form and strength INJECTABLE;INJECTION - 11MG/VIAL Sponsor ABLYNX NV Submission history Latest submission status date: 2025-12-23 00:00:00.
Structured Monograph
Clinical summary
Approval overview CABLIVI is listed in Drugs@FDA under application 761112 (BLA). Review priority: PRIORITY Marketing status: Prescription Active ingredient CAPLACIZUMAB-YHDP Form and strength INJECTABLE;INJECTION - 11MG/VIAL Sponsor ABLYNX NV Submission history Latest submission status date: 2025-12-23 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.